Background and Objective: Systemic-onset juvenile idiopathic arthritis (JIA) is a major and prevalent subset of arthritis among children and it has a broad spectrum of clinical presentation, course and prognosis. This study described the clinical presentation of systemic-onset JIA in a Saudi-based cohort. Methods: A retrospective chart review was performed of the medical records of children with systemic-onset JIA who were followed up at King Abdul Aziz University Hospital, Jeddah, between January 1997 and December 2013. Patients’ files were reviewed for demographic, clinical, and paraclinical data, which were analyzed using the statistical Package for the Social Sciences. Results: We included 20 patients of both genders (8 boys and 12 girls). The mean age of disease onset was 7 (4.5) years. The most common presenting symptoms were fever (100%), arthritis (100%), and rash (55%). Hepatomegaly (5%), abdominal (5%) and pulmonary manifestations (3%) were less frequent manifestations. Most patients had high white blood cell counts (50%), elevated erythrocyte sedimentation rates (80%) and C-reactive protein levels (90%). The interval between onset of symptoms and diagnosis was 9.4 (12.5) weeks. Patients were treated with non-steroidal anti-inflammatory drugs, methotrexate, steroids, anti-tumor necrosis agents, and disease-modifying anti-rheumatic drugs. Bone marrow biopsy was conducted to exclude malignancy in 20% of the patients. Conclusion: Saudi children with systemic-onset JIA present with prolonged fever and arthritis (mainly oligoarticular rather than polyarticular). Physicians should be aware of the presentation of systemic-onset JIA in our setting in order to make prompt diagnosis and treatment decisions as early as possible. Carful follow-up of febrile patients is paramount to reaching the diagnosis early and initiating treatment.
In 1897, Sir George Fredrick Still described three patterns of arthritis in 19 patients [
Systemic-onset JIA is classified as a subset of JIA, which constitutes 10% - 15% of all JIA cases [
The course of systemic onset JIA is variable. It can involve many organ systems, and disease activity changes with time [
The purpose of this review was to describe the clinical presentation of systemic-onset JIA in a Saudi-based cohort. To the best of our knowledge, only one study were reported the clinical presentation of Saudi patients with systemic-onset JIA [
A retrospective chart review was performed of the medical records of all cases of systemic-onset JIA that were diagnosed at the Pediatric Department of King Abdulaziz University Hospital between January 1997 and December 2013. Patients were included provided they had a diagnosis of systemic JIA diagnosed as per the criteria of the ILAR (
For all patients included in this study, we documented the following data: gender, age of presentation, family history, clinical manifestations, physical findings, laboratory data, results of imaging studies, treatment received, and complications.
Statistical AnalysisThe data were entered and analyzed using the Statistical Package for the Social Sciences (SPSS Inc., Chicago, IL, US), version 20. Descriptive statistics were computed for all variables. Results are expressed as frequencies, percentages, means and (standard deviation (SD)).
Arthritis with or preceding daily fever with a duration of at least two weeks accompanied by at least one of the following symptoms during the first six months. |
---|
– Erythematous rash; – Lymphadenopathy; – Hepatomegaly and/or splenomegaly; – Serositis. |
Exclusion criteria |
– Psoriasis or history of psoriasis in the patient or first degree relative; – Arthritis in a boy (six year-old or more) positive for HLA-B27; – Ankylosing spondylitis, enthesitis with arthritis, sacroiliitis and inflammatory bowel disease, Reiter syndrome or acute anterior uveitis in a first degree relative; – Presence of rheumatoid factor type IgM confirmed in an interval of at least three months apart. |
Abbreviations: HLA: Human leukocyte antigen; Ig: Immunoglobulin.
We enrolled 20 patients aged 3 to 12 years (mean, 11.25 years). Females comprised a larger proportion of the sample (n = 12; 60%). The mean (SD) age of disease onset was 7 (4.5) years (range, 112 years). The mean interval between the onset of symptoms and diagnosis was 9.2 (12.5) weeks (range, three weeks to one year).
The clinical manifestations of systemic-onset JIA in our patients are summarized in
The most commonly encountered features of systemic-onset JIA in our cohort were fever (n = 20; 100%), rash (n = 11; 55%) and arthritis (n = 20; 100%). The average duration of fever in the sample was 5 (10.6) months. Patients developed arthritis either early in the course of the disease or within a few weeks from the onset of fever. Most of the patients (n = 16; 80%) had an oligoarticular pattern; only four patients (20%) had a polyarticular pattern. The most frequently involved joints were the knees (n = 16; 80%), ankles (n = 14; 70%), and wrists (n = 8; 40%). Shoulder and interphalangeal joint involvement accounted for three cases (15%) each.
Lymphadenopathy was detected in four patients (20%). Cervical, inguinal, and axillary lymph node groups were involved. Splenomegaly was documented in four patients (20%), while hepatomegaly was reported in one case (5%). Four patients (20%) had experienced pericarditis during the course of their illness.
Regarding the patients’ laboratory results, hemoglobin levels were low for age in 85% of the patients (
Co-Morbidity | Lymph Nodes | Splenome- galy | Hepatom- egaly | Rash | Joint Involvement | Fever (month) | Family History | Duration from Onset to Diagnosis (wks) | Age of Onset | Sex | Case |
---|---|---|---|---|---|---|---|---|---|---|---|
− | − | − | − | − | + | 48.00 | − | 48 | 11.0 | Male | 1 |
− | − | − | − | + | + | 0.75 | − | 3 | 5.0 | Female | 2 |
− | − | − | − | − | + | 3.00 | − | 12 | 13.0 | Male | 3 |
− | − | − | − | − | + | 0.75 | − | 4 | 13.0 | Male | 4 |
− | − | − | − | − | + | 0.50 | − | 16 | 1.0 | Female | 5 |
− | − | − | − | − | + | 0.75 | + | 5 | 1.5 | Male | 6 |
− | − | − | − | − | + | 7.00 | − | 40 | 10.0 | Female | 7 |
− | − | + | − | − | + | 0.54 | − | 4 | 7.0 | Male | 8 |
− | + | + | − | + | + | 0.54 | − | 3 | 2.0 | Male | 9 |
Pericarditis | + | + | − | + | + | 0.50 | − | 4 | 10.0 | Female | 10 |
− | + | − | − | + | + | 7.00 | − | 7 | 4.0 | Female | 11 |
− | − | + | + | + | + | 12.00 | + | 12 | 2.0 | Female | 12 |
− | − | − | − | + | + | 2.00 | + | 4 | 2.0 | Female | 13 |
− | − | − | − | + | + | 0.75 | − | 3 | 7.0 | Female | 14 |
− | − | − | − | − | + | 5.00 | − | 5 | 3.0 | Male | 15 |
Pericarditis | + | + | − | + | + | 0.25 | − | 3 | 3.0 | Male | 16 |
Pericarditis | − | − | − | − | + | 0.50 | − | 2 | 15.0 | Female | 17 |
Pericarditis | − | − | − | + | + | 0.50 | − | 3 | 7.0 | Female | 18 |
− | − | − | − | + | + | 6.00 | − | 6 | 8.0 | Female | 19 |
− | − | − | − | + | + | 2.00 | − | 3 | 12.0 | Female | 20 |
Hemoglobin g/dl | WBC (4.5 - 13.5 K/UL) | Neut (35% - 65%) | PLT (150 - 450 K/UL) | ESR (1 - 20 mm/H ) | CRP (0 - 3 mg/l ) | RF (0 - 20 IU/L) | ANA | Anti MCV | C3 (0.75 - 1.65 g/L) | C4 (0.2 - 0.6 g/L ) | ALT (30 - 65 U/L) | AST (15 - 37 U/L) | Albumin (34 - 50 g/L) | Ferritin (30 - 400 ng/ml) | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | low | 5.8 | 54.2 | 590 | 78 | 119 | <9.8 | mildly positive | - | 1.9 | 0.231 | 21 | 21 | 21 | 873.8 |
2 | low | 10.9 | 69.4 | 478 | 101 | 79.6 | <9.6 | negative | - | - | - | 51 | 26 | 24 | none |
3 | low | 15.05 | 68 | 489 | 88 | 171 | 10.1 | negative | - | 2.22 | - | 7 | 26 | 26 | 14 |
4 | low | 10.2 | 71.5 | 425 | 18 | 3.41 | 10 | not done | - | - | - | 22 | 35 | 35 | none |
5 | normal | 6.03 | 43.5 | 345 | 6 | - | negative | - | - | - | 19 | 38 | 38 | none | |
6 | low | 8.4 | 41.2 | 458 | 99 | 174 | <7.3 | negative | - | - | - | 29 | 25 | 25 | none |
7 | low | 21.22 | 87.6 | 401 | 45 | 17.6 | 10.1 | negative | 14.7 | - | - | 16 | 36 | 36 | 311.8 |
8 | low | 18 | 69 | 990 | 66 | 104 | 0 | - | - | - | - | 25 | 22 | 29 | 34.8 |
9 | low | 21.5 | 17 | 597 | 117 | 222 | negative | mildly positive | - | 1.71 | 0.289 | 50 | 27 | 23 | none |
10 | low | 27.25 | 94.3 | 352 | 79 | 298 | 10.6 | negative | - | 1.86 | 0.42 | 41 | 20 | 20 | 2000 |
11 | low | 10.2 | 49 | 726 | 81 | 70 | - | negative | - | - | - | 19 | 26 | 26 | 505 |
12 | low | 11.9 | 20.8 | 382 | 16 | 3.3 | <8.7 | negative | - | 1.71 | 0.266 | 29 | 33 | 33 | 24.5 |
13 | low | 16.7 | 45 | 973 | 64 | 120 | - | negative | - | 1.16 | 0.193 | 38 | 36 | 28 | none |
14 | low | 16.3 | 81.7 | 420 | 91 | 118 | 0 | negative | - | 0.76 | 0.46 | 16 | 27 | 27 | none |
15 | low | 21.3 | 66.3 | 623 | 53 | 198 | 10.1 | negative | 22 | - | - | 19 | 33 | 33 | 736.6 |
16 | low | 11.3 | 73 | 358 | 110 | 97.4 | <9 | negative | - | 1.78 | 0.374 | 192 | 31 | 19 | none |
17 | low | 12 | 40 | 234 | 40 | 30 | negative | negative | - | - | - | 34 | 33 | 29 | none |
18 | normal | 12 | 10 | 261 | 66 | 166 | negative | negative | - | 1.92 | 0.28 | 24 | 31 | 30 | none |
19 | low | 14.17 | 85 | 334 | 99 | 164 | <10 | negative | - | 1.92 | 0.28 | 24 | 31 | 27 | 4295 |
20 | normal | 18.3 | 81 | 922 | not done | not done | <10 | negative | - | 1.34 | 0.2 | 24 | 12 | 34 | none |
Abbreviations: ALT: Alanine transaminase; ANA: Anti-nuclear antibody; AST: Aspartate aminotransferase; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; MCV: Modified citrullinated vimentin; Neut: Neutrophils; PLT: Platelet; RF: Rheumatoid factor; WBC: White blood cell; -: Not done.
platelet count of 990 K/µL was documented in one of the patients. Inflammatory markers were high in most patients, and up to 18 patients (90%) had high levels of C-reactive protein (range, 3.4 to 298 mg/L). The erythrocyte sedimentation rate was elevated in 16 patients (80%; range, 6 - 117 mm/ hour). Only one patient (5%) had impaired liver function tests, while low albumin levels were documented in 13 patients (65%). Ferritin levels were high in four (44.4%) of the patients who did the test.
Antinuclear antibody titer was positive in two patients (10%). Rheumatoid factor was negative in all the patients. Two patients who were tested for antibodies against a modified citrullinated vimentin (anti MCV) had positive results. There was no decrease in C3 and C4 levels in our cohort. The mean serum C3 concentration was 1.73 (0.42) g/dL (reference range, 0.75 - 1.65 g/L), while mean C4 concentration was 0.30 (0.1) g/dL (reference range, 0.2 - 0.6 g/L).
Bone marrow aspiration was done to exclude malignancy in four patients (20%).
Imaging studies, including magnetic resonance imaging (MRI), X-rays, and abdominal ultrasound were performed in six patients (30%). One patient had multiple gallstones on ultrasound examination. Three patients showed evidence of joint damage, as demonstrated by the presence of lumbar lordosis, acetabular dysplasia, and severe narrowing of the hip joint on MRI and X-ray images.
Regarding treatment, all the patients received non-steroidal anti-inflammatory drugs (NSAIDs). Steroids were also prescribed in cases where NSAIDs were ineffective (n = 15; 75%). Methotrexate was also administered in 17 cases (85%). Four patients received etanercept, an anti-tumor necrosis factor agent. Three patients were started on tocilizumab (a humanized anti-interleukin 6 receptor antibody). Six patients were treated with adalimumab (a tumor necrosis factor inhibitor).
Systemic onset JIA is becoming more recognized among the Saudi society. Its diagnosis is based on clinical presentation, which makes it difficult for physicians to recognize the disease early. The variability and overlap of disease symptoms as well as lack of specific biomarkers pose an additional challenge to physicians [
In our study, we found that the main presenting symptoms, namely fever, rash, and arthritis, were similar to those reported in studies conducted abroad [
Articular Deformity | Articular Damage | Limb Discrepancy | Short Stature | Bone Fracture | Avascular Necrosis | Liver Damage | Anemia | Psychological Disorders | Uveitis | Cushingoid Features | |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | + | + | − | + | − | − | − | − | − | − | − |
2 | + | + | − | − | − | − | − | − | − | − | − |
3 | − | − | − | − | − | − | − | − | − | − | + |
4 | − | − | − | − | − | − | − | − | − | − | − |
5 | − | − | − | − | − | − | − | − | − | − | − |
6 | − | − | − | − | − | − | − | − | − | − | + |
7 | − | − | − | − | − | − | − | − | − | − | − |
8 | − | − | − | + | − | − | − | − | − | − | + |
9 | − | − | − | − | − | − | − | − | − | − | − |
10 | − | − | − | − | − | − | − | + | + | − | + |
11 | − | + | − | + | − | − | − | + | + | − | + |
12 | − | − | − | − | − | − | − | − | − | − | − |
13 | − | − | − | + | − | − | − | + | − | − | + |
14 | − | − | − | − | − | − | − | − | − | − | − |
15 | − | − | − | + | + | − | − | + | − | − | + |
16 | + | + | + | + | + | + | − | + | + | − | + |
17 | − | − | − | − | − | − | − | + | − | − | − |
18 | − | − | − | − | − | − | − | − | − | − | − |
19 | − | − | − | − | − | − | − | + | − | − | − |
20 | − | − | − | − | − | − | − | + | − | − | − |
1Only cushingoid features and short stature are considered complications due to steroid use; all other complications could be caused by both the disease and steroids. Abbreviations: +: Positive; −: Negative.
years reported by Yeh et al., who investigated the clinical investigations in 16 Taiwan children [
The pattern of arthritis was predominantly oligoarticular in our patients (80%). Tsai et al. [
The prevalence of multiple diseases that could present initially with fever only might be an important factor in delaying the diagnosis in many patients. Most probably this cause lie behind the prolonged time between onset and diagnosis as many investigation are undertaken to exclude other differentials, for example, bone marrow aspiration, which is an invasive procedure, had to be performed in most of our patients to rule out malignancy. Further, the evolutional nature of disease symptoms contributes to this delay [
Systemic-onset JIA is a subset of JIA that is common in Saudi Arabia. In 1997, Baharbi et al. [
Although our study provides an insight into the clinical presentation of systemic-onset JIA in our patients, its limitations cannot be overlooked. First, it is limited by its retrospective design. Second, it was a single-center hospital based study, and the findings cannot be therefore extrapolated to the population of Jeddah.
Overall, while our patients have arthritis with a predominantly oligoarticular pattern contrary to those in studies conducted abroad, the clinical presentation of the disease is similar. A high index of suspicion should be considered in order to identify patients with systemic-onset JIA and consequently initiate treatment as early as possible. Careful follow-up of febrile patients is paramount to making a prompt diagnosis and initiating treatment.